Data from the liver cancer cohort of the cabozantinib phase 2 randomized discontinuation trail were presented at the 2012 Gastrointestinal Cancers Symposium in a poster session on Friday, January 20, 2012.
GASTROINTESTINAL CANCERS SYMPOSIUM 2012
Data Presentations
| Title | Date |
|---|---|
| Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results from a Phase 2 Randomized Discontinuation Trial (RDT) (Abstract 261; Poster C25) | Friday, January 20, 2012 - 11:45am PST |